Honglian Li

机构：Guangdong Pharmaceutical University, Huazhong University of Science and Technology, Southern Medical University · ORCID：0000-0002-7682-6525

发表论文 56 篇 · 总被引 925 次 · h-index 17

代表论文

• A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies (2021 · Signal Transduction and Targeted Therapy · 被引 75)
• Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-κB signaling and NLRP3 inflammasome activation by exosomes in rats (2019 · Biochemical Pharmacology · 被引 74)
• Zhen-wu-tang ameliorates membranous nephropathy rats through inhibiting NF-κB pathway and NLRP3 inflammasome (2019 · Phytomedicine · 被引 71)
• Paeoniflorin Inhibits Mesangial Cell Proliferation and Inflammatory Response in Rats With Mesangial Proliferative Glomerulonephritis Through PI3K/AKT/GSK-3β Pathway (2019 · Frontiers in Pharmacology · 被引 56)
• Zhen-Wu-Tang Protects IgA Nephropathy in Rats by Regulating Exosomes to Inhibit NF-κB/NLRP3 Pathway (2020 · Frontiers in Pharmacology · 被引 48)
• HIF-1α Causes LCMT1/PP2A Deficiency and Mediates Tau Hyperphosphorylation and Cognitive Dysfunction during Chronic Hypoxia (2022 · International Journal of Molecular Sciences · 被引 38)